Cancer surgery: the last 25 years.

Abstract:

:Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic facilities, novel and perfected adjuvant treatments, improved surgical techniques and daring challenges to established dogmas have all contributed to the development of surgical oncology. The heritage from the past came under close scrutiny, and the fruits of basic and clinical science were added to an ever expanding body of knowledge. It is impossible to review all developments in surgical oncology of the last 25 years in one comprehensive paper. Therefore we have restricted ourselves to those items that appear most representative for the changes that have taken place, and those diseases that have the greatest numerical impact.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Bremers AJ,Rutgers EJ,van de Velde CJ

doi

10.1053/ctrv.1999.0147

keywords:

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

333-53

issue

6

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(99)90147-0

journal_volume

25

pub_type

历史文章,杂志文章,评审
  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.

    abstract::Management of early stages non-small cell lung carcinoma has traditionally been surgery with radiation selected for medically inoperable patients. Recent emergence of stereotactic body radiation therapy allows for delivery of high radiation dose to the tumor while sparing normal lungs. This reviews compares loco-regio...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.06.001

    authors: Nguyen NP,Garland L,Welsh J,Hamilton R,Cohen D,Vinh-Hung V

    更新日期:2008-12-01 00:00:00

  • Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

    abstract::Lung cancer represents the most common cause of brain dissemination. Oncogene-addicted (EGFR- and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized by a unique metastatic neurotropism resulting in a particularly high incidence of brain metastases. The goal of optimal brain metastases management is t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.10.011

    authors: Wrona A,Dziadziuszko R,Jassem J

    更新日期:2018-12-01 00:00:00

  • The expanding role of immunotherapy.

    abstract::The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landsc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.01.008

    authors: Martin-Liberal J,Ochoa de Olza M,Hierro C,Gros A,Rodon J,Tabernero J

    更新日期:2017-03-01 00:00:00

  • Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

    abstract::In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(83)80013-9

    authors: Scheulen ME,Niederle N,Bremer K,Schütte J,Seeber S

    更新日期:1983-09-01 00:00:00

  • Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.

    abstract:OBJECTIVES:To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). DATA SOURCES:PubMed and the Cochrane Library Central Registry of Controlled Trials. REVIEW METHODS:We retrieved all randomized controlled trials compar...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2009.05.005

    authors: Golfinopoulos V,Pentheroudakis G,Salanti G,Nearchou AD,Ioannidis JP,Pavlidis N

    更新日期:2009-11-01 00:00:00

  • Tolerability and safety of rituximab (MabThera).

    abstract::Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was est...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.05.007

    authors: Kimby E

    更新日期:2005-10-01 00:00:00

  • Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

    abstract::While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.05.009

    authors: Belani CP,Goss G,Blumenschein G Jr

    更新日期:2012-05-01 00:00:00

  • Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

    abstract::In metastatic colorectal cancer (mCRC), fluorouracil-based combination therapy with oxaliplatin or irinotecan is the mainstay of first-line treatment. Patient survival has been significantly improved with the introduction of monoclonal antibodies against VEGF (bevacizumab), VEGFR2 (ramucirumab) or EGFR (cetuximab or p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.10.006

    authors: Sartore-Bianchi A,Siena S,Tonini G,Bardelli A,Santini D

    更新日期:2016-12-01 00:00:00

  • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

    abstract::Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.012

    authors: McDermott D,Lebbé C,Hodi FS,Maio M,Weber JS,Wolchok JD,Thompson JA,Balch CM

    更新日期:2014-10-01 00:00:00

  • Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.

    abstract::Solid tumours contain regions of hypoxia, which may be a prognostic indicator and determinant of malignant progression, metastatic development and chemoradio-resistance. The degree of intra-tumoural hypoxia has been shown to be positively correlated with the expression of the transcription factor hypoxia-inducible fac...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.05.003

    authors: O'Donnell JL,Joyce MR,Shannon AM,Harmey J,Geraghty J,Bouchier-Hayes D

    更新日期:2006-10-01 00:00:00

  • DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?

    abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.03.125

    authors: Johannessen TC,Bjerkvig R,Tysnes BB

    更新日期:2008-10-01 00:00:00

  • Megestrol acetate: clinical experience.

    abstract::The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity pro...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(89)90004-2

    authors: Schacter L,Rozencweig M,Canetta R,Kelley S,Nicaise C,Smaldone L

    更新日期:1989-03-01 00:00:00

  • Fertility preservation in women with borderline ovarian tumours.

    abstract::Borderline ovarian tumours (BOT) may occur in young women and have an excellent survival rate. Therefore, there is the obligation to put emphasis on fertility preservation in affected women. On the other hand, it has also been underlined that the disease should be managed with caution because these tumours can relapse...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.06.010

    authors: Mangili G,Somigliana E,Giorgione V,Martinelli F,Filippi F,Petrella MC,Candiani M,Peccatori F

    更新日期:2016-09-01 00:00:00

  • Bisantrene, biological and clinical effects.

    abstract::The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(84)90024-0

    authors: Coltman CA Jr,Osborne CK

    更新日期:1984-12-01 00:00:00

  • Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.

    abstract::In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician's therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently considered as potential an...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.09.002

    authors: Soultati A,Mountzios G,Avgerinou C,Papaxoinis G,Pectasides D,Dimopoulos MA,Papadimitriou C

    更新日期:2012-08-01 00:00:00

  • The Notch-1 receptor in prostate tumorigenesis.

    abstract::The Notch signalling pathway plays a fundamental role in tissue development due to its involvement in cell fate determination and postnatal tissue differentiation. Its capacity to regulate cell growth and development has been linked to the occurrence of several cancers including that of the prostate. The transmembrane...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.04.003

    authors: O'Brien R,Marignol L

    更新日期:2017-05-01 00:00:00

  • Prevention of chemotherapy and radiation toxicity with glutamine.

    abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00133-6

    authors: Savarese DM,Savy G,Vahdat L,Wischmeyer PE,Corey B

    更新日期:2003-12-01 00:00:00

  • Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

    abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.06.008

    authors: Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

    更新日期:2014-02-01 00:00:00

  • Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.

    abstract::Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.10.004

    authors: Pantaleo MA,Nannini M,Di Battista M,Catena F,Biasco G

    更新日期:2010-02-01 00:00:00

  • Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review.

    abstract::Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGFR) mutation or anaplastic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.05.005

    authors: Hendriks LE,Schoenmaekers J,Zindler JD,Eekers DB,Hoeben A,De Ruysscher DK,Dingemans AM

    更新日期:2015-07-01 00:00:00

  • Adjuvant therapy in colon cancer: current status and future directions.

    abstract::The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00047-6

    authors: Chau I,Cunningham D

    更新日期:2002-10-01 00:00:00

  • Beyond BRCA: new hereditary breast cancer susceptibility genes.

    abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.008

    authors: Economopoulou P,Dimitriadis G,Psyrri A

    更新日期:2015-01-01 00:00:00

  • Maintenance chemotherapy for non-small-cell lung cancer.

    abstract::Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confir...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.12.007

    authors: Kim YH,Mishima M

    更新日期:2011-11-01 00:00:00

  • Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

    abstract::The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.04.001

    authors: Skrzypski M,Jassem J

    更新日期:2018-05-01 00:00:00

  • Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

    abstract::Biliary tract cancers (BTCs) are a group of invasive neoplasms, with increasing incidence and dismal prognosis. In advanced disease, the standard of care is represented by first-line chemotherapy with cisplatin and gemcitabine. In subsequent lines, no clear recommendations are currently available, highlighting the nee...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.11.001

    authors: Corti F,Nichetti F,Raimondi A,Niger M,Prinzi N,Torchio M,Tamborini E,Perrone F,Pruneri G,Di Bartolomeo M,de Braud F,Pusceddu S

    更新日期:2019-01-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Update on capecitabine alone and in combination regimens in colorectal cancer patients.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/S0305-7372(10)70020-7

    authors: Silvestris N,Maiello E,De Vita F,Cinieri S,Santini D,Russo A,Tommasi S,Azzariti A,Numico G,Pisconti S,Petriella D,Lorusso V,Millaku A,Colucci G

    更新日期:2010-11-01 00:00:00

  • Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.

    abstract:PURPOSE:To evaluate the existing evidence regarding the long-term risk of cardiovascular disease (CVD) after radiotherapy for childhood cancer. PATIENTS AND METHODS:MEDLINE and EMBASE were searched for articles reporting on radiation-induced CVD after childhood cancer published between 1966 and October 2002. Informati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.03.008

    authors: van der Pal HJ,van Dalen EC,Kremer LC,Bakker PJ,van Leeuwen FE

    更新日期:2005-05-01 00:00:00

  • Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.

    abstract::Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provid...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.04.001

    authors: Bhatt VR

    更新日期:2019-05-01 00:00:00